NM_058216.3:c.890T>C
Variant summary
Our verdict is Uncertain significance. Variant got 0 ACMG points: 0P and 0B.
The NM_058216.3(RAD51C):āc.890T>Cā(p.Leu297Pro) variant causes a missense change. The variant allele was found at a frequency of 0.0000279 in 1,611,706 control chromosomes in the GnomAD database, with no homozygous occurrence. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_058216.3 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Uncertain_significance. Variant got 0 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes AF: 0.000158 AC: 24AN: 152214Hom.: 0 Cov.: 31
GnomAD3 exomes AF: 0.0000319 AC: 8AN: 251048Hom.: 0 AF XY: 0.0000221 AC XY: 3AN XY: 135742
GnomAD4 exome AF: 0.0000144 AC: 21AN: 1459492Hom.: 0 Cov.: 30 AF XY: 0.00000413 AC XY: 3AN XY: 726194
GnomAD4 genome AF: 0.000158 AC: 24AN: 152214Hom.: 0 Cov.: 31 AF XY: 0.000134 AC XY: 10AN XY: 74366
ClinVar
Submissions by phenotype
not provided Uncertain:3
The RAD51C c.890T>C (p.Leu297Pro) variant has been reported in the published literature in individuals with sporadic pancreatic cancer (PMID: 28767289 (2017)) and history of Lynch syndrome-associated cancer and/or polyps (PMID: 25980754 (2015)). It has also been observed in a cohort of individuals with prostate cancer and reportedly healthy individuals (PMID: 32832836 (2020)). The frequency of this variant in the general population, 0.00052 (13/24946 chromosomes (Genome Aggregation Database, http://gnomad.broadinstitute.org)), is uninformative in the assessment of its pathogenicity. Analysis of this variant using bioinformatics tools for the prediction of the effect of amino acid changes on protein structure and function yielded predictions that this variant is damaging. Based on the available information, we are unable to determine the clinical significance of this variant. -
Published functional studies demonstrate homology-directed repair activity comparable to wild-type (PMID: 37253112); In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; This variant is associated with the following publications: (PMID: 28767289, 34923718, 25980754, 14704354, 37253112) -
- -
Hereditary cancer-predisposing syndrome Uncertain:3
The p.L297P variant (also known as c.890T>C), located in coding exon 6 of the RAD51C gene, results from a T to C substitution at nucleotide position 890. The leucine at codon 297 is replaced by proline, an amino acid with similar properties. This alteration has been reported in a cohort of 854 patients with apparently sporadic pancreatic cancer (Shindo K et al. J. Clin. Oncol., 2017 Oct;35:3382-3390). This amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. -
- -
This missense variant replaces leucine with proline at codon 297 of the RAD51C protein. Computational prediction suggests that this variant may not impact protein structure and function (internally defined REVEL score threshold <= 0.5, PMID: 27666373). To our knowledge, functional studies have not been reported for this variant. This variant has been reported in one individual each affected with triple-negative breast cancer (https://austinpublishinggroup.com/cancer-clinical-research/fulltext/cancer-v5-id1082.pdf), Lynch syndrome-associated cancer and/or polyps (PMID: 25980754) and gallbladder cancer (PMID: 28767289). This variant has been identified in 13/282450 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. -
Breast-ovarian cancer, familial, susceptibility to, 3 Uncertain:2Benign:1
- -
This variant is considered likely benign. This variant is strongly associated with less severe personal and family histories of cancer, typical for individuals without pathogenic variants in this gene [PMID: 25085752]. -
- -
not specified Uncertain:2
Variant summary: RAD51C c.890T>C (p.Leu297Pro) results in a non-conservative amino acid change located in the DNA recombination and repair protein Rad51-like, C-terminal domain (IPR013632) of the encoded protein sequence. Four of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 3.2e-05 in 251048 control chromosomes, predominantly at a frequency of 0.00049 within the African or African-American subpopulation in the gnomAD database. The available data on variant occurrences in the general population are insufficient to allow any conclusion about variant significance. c.890T>C has been reported in the literature as a VUS in settings of multigene panel testing of individuals affected with/undergoing testing for Lynch syndrome, apparently sporadic pancreatic cancer (example, Yurgelun_2015, Shindo_2017) and in settings of integrated genomic profiling for patients with cancer (example, Beaubier_2019). These report(s) do not provide unequivocal conclusions about association of the variant with Hereditary Breast And Ovarian Cancer Syndrome/RAD51C-related disorders. To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. Eight clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014 without evidence for independent evaluation. All laboratories classified the variant as uncertain significance. Based on the evidence outlined above, the variant was classified as uncertain significance. -
- -
Fanconi anemia complementation group O Uncertain:2
This sequence change replaces leucine, which is neutral and non-polar, with proline, which is neutral and non-polar, at codon 297 of the RAD51C protein (p.Leu297Pro). This variant is present in population databases (rs143026267, gnomAD 0.05%). This missense change has been observed in individual(s) with gall bladder adenocarcinoma and an individual undergoing testing for Lynch syndrome (PMID: 25980754, 28767289). ClinVar contains an entry for this variant (Variation ID: 186828). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt RAD51C protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. -
- -
Fanconi anemia complementation group O;C3150659:Breast-ovarian cancer, familial, susceptibility to, 3 Uncertain:1
- -
RAD51C-related disorder Uncertain:1
The RAD51C c.890T>C variant is predicted to result in the amino acid substitution p.Leu297Pro. This variant has been reported in an individual with non-pancreatic ductal adenocarcinoma of the gallbladder (Table A2, Shindo et al. 2017. PubMed ID: 28767289), an individual with ovarian cancer (Table S1, Boni et al. 2022. PubMed ID: 34923718), and in a patient undergoing genetic testing for Lynch syndrome (Table S2, Yurgelun et al. 2015. PubMed ID: 25980754). This variant is reported in 0.052% of alleles in individuals of African descent in gnomAD and has been interpreted as variant of uncertain significance in the ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/variation/186828/). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at